Shots: KSQ to receive $100M+ as up front and preclinical milestones and up to $400M+/ program in option payment and development & commercialization milestones along with royalties on sales of […]readmore
Tags : Immuno-Oncology Therapies
Shots: Carna to receive $20M upfront, up to $450M as development & commercial milestones and royalties on sales. Gilead to get WW rights to develop and commercialize inhibitors against immuno-oncology […]readmore
Shots: NextCure to get $25M upfront plus milestones & royalty payments in addition to $15M equity investments. NextCure & Lilly will hold equal rights to exclusively license the Abs The […]readmore